Onconetix Secures Nasdaq Listing with Panel Decision

The latest update is out from Onconetix ( (ONCO) ).

On June 16, 2025, Onconetix, Inc. announced that it received a favorable decision from the Nasdaq Hearings Panel, allowing the company to continue its listing on The Nasdaq Stock Market. This decision is contingent upon Onconetix demonstrating compliance with specific Nasdaq Listing Rules by the end of June 2025. The company has already met the Periodic Filing Listing Rule as of June 12, 2025, and completed a reverse stock split to aid in meeting the Bid Price Listing Rule by June 27, 2025. The announcement highlights Onconetix’s efforts to maintain its Nasdaq listing, which is crucial for its market presence and investor confidence.

Spark’s Take on ONCO Stock

According to Spark, TipRanks’ AI Analyst, ONCO is a Underperform.

Onconetix’s overall score reflects substantial financial difficulties with significant operating losses and negative profitability metrics. The technical analysis suggests a bearish trend, and the valuation metrics are unfavorable due to negative earnings. These factors combine to give the stock a low attractiveness score.

To see Spark’s full report on ONCO stock, click here.

More about Onconetix

Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union.

Average Trading Volume: 286,925

Technical Sentiment Signal: Sell

Current Market Cap: $2.47M

See more insights into ONCO stock on TipRanks’ Stock Analysis page.